Plain-English translation of NCT03670966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment approach for patients with serious blood cancers like leukemia or myelodysplastic syndrome that haven't responded well to standard chemotherapy. The study combines a targeted radiation therapy called 211At-BC8-B10 with chemotherapy and a stem cell transplant from a family member. Researchers believe this combination may help destroy cancer cells more effectively while preparing your body to accept the new healthy stem cells.
Many patients with advanced blood cancers do not survive with current standard treatments. This medication is designed to deliver radiation directly to cancer cells while sparing healthy tissue, which may improve survival rates and reduce side effects compared to traditional approaches.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication as an infusion, followed by chemotherapy and low-dose whole body radiation to prepare your body for transplant. On day zero, you receive stem cells from your matched family member donor. After transplant, you take medications to prevent rejection and support blood cell recovery, with regular blood draws and bone marrow biopsies to monitor your progress. You would be followed closely with visits at day 100, and then at 6, 9, 12, 18, and 24 months after transplant.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States